— Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma
May 13, 2026
• 2 min read
The FDA granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin lymphoma.
A next-generation product in the drug class, sonrotoclax is indicated for adults previously treated with two or more lines of therapy that includes a Bruton's tyrosine kinase (BTK) inhibitor.
